Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 181

1.

The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence.

Clark SD, Abi-Dargham A.

Biol Psychiatry. 2019 May 22. pii: S0006-3223(19)31379-4. doi: 10.1016/j.biopsych.2019.05.012. [Epub ahead of print] Review.

2.

Effects of L-DOPA Monotherapy on Psychomotor Speed and [11C]Raclopride Binding in High-Risk Older Adults With Depression.

Rutherford BR, Slifstein M, Chen C, Abi-Dargham A, Brown PJ, Wall MW, Vanegas-Arroyave N, Stern Y, Bailey V, Valente E, Roose SP.

Biol Psychiatry. 2019 Aug 1;86(3):221-229. doi: 10.1016/j.biopsych.2019.04.007. Epub 2019 Apr 15.

PMID:
31178096
3.

Letter to the Editor: A Novel Therapeutic for Opioid Use Disorder Targeting the Cholinergic System.

Moeller SJ, Abi-Dargham A.

Am J Addict. 2019 Jul;28(4):235-237. doi: 10.1111/ajad.12906. Epub 2019 Jun 4. No abstract available.

PMID:
31165540
4.

Effects of acute N-acetylcysteine challenge on cortical glutathione and glutamate in schizophrenia: A pilot in vivo proton magnetic resonance spectroscopy study.

Girgis RR, Baker S, Mao X, Gil R, Javitt DC, Kantrowitz JT, Gu M, Spielman DM, Ojeil N, Xu X, Abi-Dargham A, Shungu DC, Kegeles LS.

Psychiatry Res. 2019 May;275:78-85. doi: 10.1016/j.psychres.2019.03.018. Epub 2019 Mar 12.

PMID:
30884334
5.

Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain.

Cassidy CM, Zucca FA, Girgis RR, Baker SC, Weinstein JJ, Sharp ME, Bellei C, Valmadre A, Vanegas N, Kegeles LS, Brucato G, Jung Kang U, Sulzer D, Zecca L, Abi-Dargham A, Horga G.

Proc Natl Acad Sci U S A. 2019 Mar 12;116(11):5108-5117. doi: 10.1073/pnas.1807983116. Epub 2019 Feb 22.

PMID:
30796187
6.

Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms.

McCutcheon RA, Abi-Dargham A, Howes OD.

Trends Neurosci. 2019 Mar;42(3):205-220. doi: 10.1016/j.tins.2018.12.004. Epub 2019 Jan 6. Review.

7.

From "bedside" to "bench" and back: A translational approach to studying dopamine dysfunction in schizophrenia.

Abi-Dargham A.

Neurosci Biobehav Rev. 2018 Dec 5. pii: S0149-7634(18)30314-2. doi: 10.1016/j.neubiorev.2018.12.003. [Epub ahead of print] Review.

PMID:
30528375
8.

Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [11C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance Imaging Study.

Schneier FR, Slifstein M, Whitton AE, Pizzagalli DA, Reinen J, McGrath PJ, Iosifescu DV, Abi-Dargham A.

Biol Psychiatry. 2018 Oct 15;84(8):563-573. doi: 10.1016/j.biopsych.2018.05.014. Epub 2018 May 25.

PMID:
30041971
9.

Enhanced Striatal Dopamine Release to Expectation of Alcohol: A Potential Risk Factor for Alcohol Use Disorder.

Kegeles LS, Horga G, Ghazzaoui R, Rosengard R, Ojeil N, Xu X, Slifstein M, Petrakis I, O'Malley SS, Krystal JH, Abi-Dargham A.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 Jul;3(7):591-598. doi: 10.1016/j.bpsc.2018.03.018. Epub 2018 Apr 21.

PMID:
29803635
10.

Is it Pre- or Postsynaptic? Imaging Striatal Dopamine Excess in Schizophrenia.

Slifstein M, Abi-Dargham A.

Biol Psychiatry. 2018 Apr 15;83(8):635-637. doi: 10.1016/j.biopsych.2018.02.015. No abstract available.

PMID:
29559095
11.

A Perceptual Inference Mechanism for Hallucinations Linked to Striatal Dopamine.

Cassidy CM, Balsam PD, Weinstein JJ, Rosengard RJ, Slifstein M, Daw ND, Abi-Dargham A, Horga G.

Curr Biol. 2018 Feb 19;28(4):503-514.e4. doi: 10.1016/j.cub.2017.12.059. Epub 2018 Feb 2.

12.

Aberrant Temporal Connectivity in Persons at Clinical High Risk for Psychosis.

Colibazzi T, Yang Z, Horga G, Chao-Gan Y, Corcoran CM, Klahr K, Brucato G, Girgis R, Abi-Dargham A, Milham MP, Peterson BS.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 Nov;2(8):696-705. doi: 10.1016/j.bpsc.2016.12.008. Epub 2017 Jan 21.

13.

PET imaging of dopamine-D2 receptor internalization in schizophrenia.

Weinstein JJ, van de Giessen E, Rosengard RJ, Xu X, Ojeil N, Brucato G, Gil RB, Kegeles LS, Laruelle M, Slifstein M, Abi-Dargham A.

Mol Psychiatry. 2017 Jul 25. doi: 10.1038/mp.2017.157. [Epub ahead of print]

PMID:
29155803
14.

Cannabis-associated psychosis: Neural substrate and clinical impact.

Murray RM, Englund A, Abi-Dargham A, Lewis DA, Di Forti M, Davies C, Sherif M, McGuire P, D'Souza DC.

Neuropharmacology. 2017 Sep 15;124:89-104. doi: 10.1016/j.neuropharm.2017.06.018. Epub 2017 Jun 17. Review.

PMID:
28634109
15.

PET imaging of dopamine-D2 receptor internalization in schizophrenia.

Weinstein JJ, van de Giessen E, Rosengard RJ, Xu X, Ojeil N, Brucato G, Gil RB, Kegeles LS, Laruelle M, Slifstein M, Abi-Dargham A.

Mol Psychiatry. 2018 Jun;23(6):1506-1511. doi: 10.1038/mp.2017.107. Epub 2017 May 16. Erratum in: Mol Psychiatry. 2017 Jul 25;:.

16.

NPP: Our Designs for the Future.

Carlezon WA Jr, Abi-Dargham A.

Neuropsychopharmacology. 2017 Jun;42(7):1371-1372. doi: 10.1038/npp.2017.54. No abstract available.

17.

Recent Developments in Molecular Brain Imaging of Neuropsychiatric Disorders.

Slifstein M, Abi-Dargham A.

Semin Nucl Med. 2017 Jan;47(1):54-63. doi: 10.1053/j.semnuclmed.2016.09.002. Epub 2016 Oct 13. Review.

PMID:
27987558
18.

A Dual Hit Model for Dopamine in Schizophrenia.

Abi-Dargham A.

Biol Psychiatry. 2017 Jan 1;81(1):2-4. doi: 10.1016/j.biopsych.2016.10.008. No abstract available.

PMID:
27876155
19.

Distinct Relationships Between Visual and Auditory Perceptual Abnormalities and Conversion to Psychosis in a Clinical High-Risk Population.

Lehembre-Shiah E, Leong W, Brucato G, Abi-Dargham A, Lieberman JA, Horga G, Girgis RR.

JAMA Psychiatry. 2017 Jan 1;74(1):104-106. doi: 10.1001/jamapsychiatry.2016.3055. No abstract available.

20.

The search for imaging biomarkers in psychiatric disorders.

Abi-Dargham A, Horga G.

Nat Med. 2016 Nov;22(11):1248-1255. doi: 10.1038/nm.4190. Epub 2016 Oct 26.

PMID:
27783066
21.

Studying schizophrenia in the post-genomic era: perspectives from the 2016 summer Banbury Workshop at Cold Spring Harbor Laboratory.

Delevich K, Abi-Dargham A, Hall J, Sawa A.

Mol Psychiatry. 2017 Jan;22(1):2-3. doi: 10.1038/mp.2016.197. Epub 2016 Oct 25. No abstract available.

PMID:
27777417
22.

Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.

Girgis RR, Slifstein M, D'Souza D, Lee Y, Periclou A, Ghahramani P, Laszlovszky I, Durgam S, Adham N, Nabulsi N, Huang Y, Carson RE, Kiss B, Kapás M, Abi-Dargham A, Rakhit A.

Psychopharmacology (Berl). 2016 Oct;233(19-20):3503-12. doi: 10.1007/s00213-016-4382-y. Epub 2016 Aug 15.

23.

Shall we really say goodbye to first rank symptoms?

Heinz A, Voss M, Lawrie SM, Mishara A, Bauer M, Gallinat J, Juckel G, Lang U, Rapp M, Falkai P, Strik W, Krystal J, Abi-Dargham A, Galderisi S.

Eur Psychiatry. 2016 Sep;37:8-13. doi: 10.1016/j.eurpsy.2016.04.010. Epub 2016 Jul 16.

PMID:
27429167
24.

Dopamine D1 signaling organizes network dynamics underlying working memory.

Roffman JL, Tanner AS, Eryilmaz H, Rodriguez-Thompson A, Silverstein NJ, Ho NF, Nitenson AZ, Chonde DB, Greve DN, Abi-Dargham A, Buckner RL, Manoach DS, Rosen BR, Hooker JM, Catana C.

Sci Adv. 2016 Jun 3;2(6):e1501672. doi: 10.1126/sciadv.1501672. eCollection 2016 Jun.

25.

Biological Psychiatry and Biological Psychiatry: Cognitive Neuroscience and Neuroimaging Adopt Neuroscience-Based Nomenclature.

Krystal JH, Abi-Dargham A, Barch DM, Bullmore ET, Carter CS, Geschwind DH, Harrison PJ, Nestler EJ, Stein MB.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2016 Jul;1(4):300-301. doi: 10.1016/j.bpsc.2016.03.007. Epub 2016 Jun 22. No abstract available.

PMID:
29560862
26.

Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research.

Krystal JH, Abi-Dargham A, Akbarian S, Arnsten AFT, Barch DM, Bearden CE, Braff DL, Brown ES, Bullmore ET, Carlezon WA Jr, Carter CS, Cook EH Jr, Daskalakis ZJ, DiLeone RJ, Duman RS, Grace AA, Hariri AR, Harrison PJ, Hiroi N, Kenny PJ, Kleinman JE, Krystal AD, Lewis DA, Lipska BK, Marder SR, Mason GF, Mathalon DH, McClung CA, McDougle CJ, McIntosh AM, McMahon FJ, Mirnics K, Monteggia LM, Narendran R, Nestler EJ, Neumeister A, O'Donovan MC, Öngür D, Pariante CM, Paulus MP, Pearlson G, Phillips ML, Pine DS, Pizzagalli DA, Pletnikov MV, Ragland JD, Rapoport JL, Ressler KJ, Russo SJ, Sanacora G, Sawa A, Schatzberg AF, Shaham Y, Shamay-Tsoory SG, Sklar P, State MW, Stein MB, Strakowski SM, Taylor SF, Turecki G, Turetsky BI, Weissman MM, Zachariou V, Zarate CA Jr, Zubieta JK.

Biol Psychiatry. 2016 Jul 15;80(2):84-86. doi: 10.1016/j.biopsych.2016.05.004. No abstract available.

27.

Biological Psychiatry and Biological Psychiatry: Cognitive Neuroscience and Neuroimaging Adopt Neuroscience-Based Nomenclature.

Krystal JH, Abi-Dargham A, Barch DM, Bullmore ET, Carter CS, Geschwind DH, Harrison PJ, Nestler EJ, Stein MB.

Biol Psychiatry. 2016 Jul 1;80(1):2-3. doi: 10.1016/j.biopsych.2016.03.2103. No abstract available.

PMID:
27312230
28.

Pathway-Specific Dopamine Abnormalities in Schizophrenia.

Weinstein JJ, Chohan MO, Slifstein M, Kegeles LS, Moore H, Abi-Dargham A.

Biol Psychiatry. 2017 Jan 1;81(1):31-42. doi: 10.1016/j.biopsych.2016.03.2104. Epub 2016 Mar 31. Review.

29.

Cannabis Abusers Show Hypofrontality and Blunted Brain Responses to a Stimulant Challenge in Females but not in Males.

Wiers CE, Shokri-Kojori E, Wong CT, Abi-Dargham A, Demiral ŞB, Tomasi D, Wang GJ, Volkow ND.

Neuropsychopharmacology. 2016 Sep;41(10):2596-605. doi: 10.1038/npp.2016.67. Epub 2016 May 9.

30.

Dopamine-Related Disruption of Functional Topography of Striatal Connections in Unmedicated Patients With Schizophrenia.

Horga G, Cassidy CM, Xu X, Moore H, Slifstein M, Van Snellenberg JX, Abi-Dargham A.

JAMA Psychiatry. 2016 Aug 1;73(8):862-70. doi: 10.1001/jamapsychiatry.2016.0178.

31.

Motivational Context Modulates Prediction Error Response in Schizophrenia.

Reinen JM, Van Snellenberg JX, Horga G, Abi-Dargham A, Daw ND, Shohamy D.

Schizophr Bull. 2016 Nov;42(6):1467-1475. doi: 10.1093/schbul/sbw045. Epub 2016 Apr 22.

32.

Dynamic Connectivity between Brain Networks Supports Working Memory: Relationships to Dopamine Release and Schizophrenia.

Cassidy CM, Van Snellenberg JX, Benavides C, Slifstein M, Wang Z, Moore H, Abi-Dargham A, Horga G.

J Neurosci. 2016 Apr 13;36(15):4377-88. doi: 10.1523/JNEUROSCI.3296-15.2016.

33.

Mechanisms of Working Memory Impairment in Schizophrenia.

Van Snellenberg JX, Girgis RR, Horga G, van de Giessen E, Slifstein M, Ojeil N, Weinstein JJ, Moore H, Lieberman JA, Shohamy D, Smith EE, Abi-Dargham A.

Biol Psychiatry. 2016 Oct 15;80(8):617-26. doi: 10.1016/j.biopsych.2016.02.017. Epub 2016 Feb 23.

34.

Deficits in striatal dopamine release in cannabis dependence.

van de Giessen E, Weinstein JJ, Cassidy CM, Haney M, Dong Z, Ghazzaoui R, Ojeil N, Kegeles LS, Xu X, Vadhan NP, Volkow ND, Slifstein M, Abi-Dargham A.

Mol Psychiatry. 2017 Jan;22(1):68-75. doi: 10.1038/mp.2016.21. Epub 2016 Mar 22.

35.

A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia.

Girgis RR, Van Snellenberg JX, Glass A, Kegeles LS, Thompson JL, Wall M, Cho RY, Carter CS, Slifstein M, Abi-Dargham A, Lieberman JA.

J Psychopharmacol. 2016 May;30(5):428-35. doi: 10.1177/0269881116636120. Epub 2016 Mar 10.

PMID:
26966119
36.

Imaging the "GABA shift" in schizophrenia.

Abi-Dargham A.

Am J Psychiatry. 2015 Nov 1;172(11):1062-3. doi: 10.1176/appi.ajp.2015.15081088. No abstract available.

PMID:
26575447
37.

Neural Dysfunction in Cognitive Control Circuits in Persons at Clinical High-Risk for Psychosis.

Colibazzi T, Horga G, Wang Z, Huo Y, Corcoran C, Klahr K, Brucato G, Girgis R, Gill K, Abi-Dargham A, Peterson BS.

Neuropsychopharmacology. 2016 Apr;41(5):1241-50. doi: 10.1038/npp.2015.273. Epub 2015 Sep 10.

38.

Integrating acquired preparedness and dual process models of risk for heavy drinking and related problems.

Corbin WR, Papova A, Morean ME, O'Malley SS, Krishnan-Sarin S, Abi-Dargham A, Anticevic A, Pearlson G, Petrakis I, Pittman BP, Krystal JH.

Psychol Addict Behav. 2015 Dec;29(4):864-74. doi: 10.1037/adb0000093. Epub 2015 Sep 7.

39.

Antipsychotic binding to the dopamine-3 receptor in humans: A PET study with [(11)C]-(+)-PHNO.

Girgis RR, Xu X, Gil RB, Hackett E, Ojeil N, Lieberman JA, Slifstein M, Abi-Dargham A.

Schizophr Res. 2015 Oct;168(1-2):373-6. doi: 10.1016/j.schres.2015.06.027. Epub 2015 Jul 17.

40.

An evaluation of the brain distribution of [(11)C]GSK1034702, a muscarinic-1 (M 1) positive allosteric modulator in the living human brain using positron emission tomography.

Ridler K, Cunningham V, Huiban M, Martarello L, Pampols-Maso S, Passchier J, Gunn RN, Searle G, Abi-Dargham A, Slifstein M, Watson J, Laruelle M, Rabiner EA.

EJNMMI Res. 2014 Dec;4(1):66. doi: 10.1186/s13550-014-0066-y. Epub 2014 Dec 5.

41.

Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study.

Slifstein M, van de Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R, Hackett E, Girgis R, Ojeil N, Moore H, D'Souza D, Malison RT, Huang Y, Lim K, Nabulsi N, Carson RE, Lieberman JA, Abi-Dargham A.

JAMA Psychiatry. 2015 Apr;72(4):316-24. doi: 10.1001/jamapsychiatry.2014.2414.

42.

Schizophrenia: overview and dopamine dysfunction.

Abi-Dargham A.

J Clin Psychiatry. 2014 Nov;75(11):e31. doi: 10.4088/JCP.13078tx2c. Review.

43.

Dynamic shifts in brain network activation during supracapacity working memory task performance.

Van Snellenberg JX, Slifstein M, Read C, Weber J, Thompson JL, Wager TD, Shohamy D, Abi-Dargham A, Smith EE.

Hum Brain Mapp. 2015 Apr;36(4):1245-64. doi: 10.1002/hbm.22699. Epub 2014 Nov 24.

44.

Molecular imaging in alcohol dependence.

Ravan S, Martinez D, Slifstein M, Abi-Dargham A.

Handb Clin Neurol. 2014;125:293-311. doi: 10.1016/B978-0-444-62619-6.00018-5. Review.

PMID:
25307582
45.

Serotonin transporter availability in impulsive aggressive personality disordered patients: a PET study with [11C]DASB.

van de Giessen E, Rosell DR, Thompson JL, Xu X, Girgis RR, Ehrlich Y, Slifstein M, Abi-Dargham A, Siever LJ.

J Psychiatr Res. 2014 Nov;58:147-54. doi: 10.1016/j.jpsychires.2014.07.025. Epub 2014 Aug 6.

PMID:
25145808
46.

Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder.

Rosell DR, Zaluda LC, McClure MM, Perez-Rodriguez MM, Strike KS, Barch DM, Harvey PD, Girgis RR, Hazlett EA, Mailman RB, Abi-Dargham A, Lieberman JA, Siever LJ.

Neuropsychopharmacology. 2015 Jan;40(2):446-53. doi: 10.1038/npp.2014.192. Epub 2014 Jul 30.

47.

Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies.

Kambeitz J, Abi-Dargham A, Kapur S, Howes OD.

Br J Psychiatry. 2014 Jun;204(6):420-9. doi: 10.1192/bjp.bp.113.132308. Review.

PMID:
25029687
48.

Deficits in predictive coding underlie hallucinations in schizophrenia.

Horga G, Schatz KC, Abi-Dargham A, Peterson BS.

J Neurosci. 2014 Jun 11;34(24):8072-82. doi: 10.1523/JNEUROSCI.0200-14.2014.

49.

Prefrontal dopamine D1 receptors and working memory in schizotypal personality disorder: a PET study with [¹¹C]NNC112.

Thompson JL, Rosell DR, Slifstein M, Girgis RR, Xu X, Ehrlich Y, Kegeles LS, Hazlett EA, Abi-Dargham A, Siever LJ.

Psychopharmacology (Berl). 2014 Oct;231(21):4231-40. doi: 10.1007/s00213-014-3566-6. Epub 2014 Apr 30.

50.

GABA level, gamma oscillation, and working memory performance in schizophrenia.

Chen CM, Stanford AD, Mao X, Abi-Dargham A, Shungu DC, Lisanby SH, Schroeder CE, Kegeles LS.

Neuroimage Clin. 2014 Mar 20;4:531-9. doi: 10.1016/j.nicl.2014.03.007. eCollection 2014.

Supplemental Content

Loading ...
Support Center